Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | SHFS 0.1324 -61.39% | XXII 0.1977 -8.34% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | RBNE 0.19 -2.56% | YFOR 0.2236 -1.58% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | TQQQ 66.29 -0.20% | TSLL 9.76 -1.21% | VZ 44.66 -1.19% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | GRAB 2.79 -2.11% | AIOK 12.02 182.82% | SQQQ 39.68 0.20% | ONDS 6.2 2.99% | LABT 0.31 -36.67% | AAPL 347.725 -0.14% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | IREN 24.905 -2.37% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | NFLX 65.85 -1.79% | QID 14.55 0.14% | CLRO 3.25 69.27% | WULF 11.32 0.00%
PHPharming Group N.V. logo

Pharming Group N.V. (PHAR)

NASDAQ Global Market · Currency in USD
$11.20 ▲ +0.53 (+4.97%)
At close: Oct 23, 4:00 PM ET. Market closed.
$11.50 ▲ +0.30 (+2.68%)
Pre-market: Oct 26, 7:00 AM ET

Summary

Previous Close
$10.67
Open
$11.32
Day's Range
$10.76 – $11.45
52 Week Range
$9.11 – $21.34
Volume
25,784
Avg. Volume
18,849
Market Cap
$792.71M
Beta (5Y Monthly)
0.09
PE Ratio (TTM)
77.12
EPS (TTM)
$0.13
Earnings Date
Oct 27, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$39.00

Profile: Pharming Group N.V.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
407
CEO
Fabrice Chouraqui

Pharming Group N.V. is a biopharmaceutical company dedicated to the creation and commercialization of protein replacement therapies and precision medicines. The firm concentrates its efforts on addressing rare diseases and critical unmet medical needs across the United States, Europe, and other international markets. Its primary commercialized product is Ruconest, a recombinant human C1 esterase inhibitor utilized for the acute treatment of hereditary angioedema.

Earnings

Next report: Tue, Oct 27, 2026
EPS estimate $0.15 · Revenue est. $117.60M
DateEst.Actual
Jul 30, 2026$0.06$0.02Miss
May 7, 2026$0.05-$0.07Miss
Mar 12, 2026$0.02$0.07Beat
Nov 6, 2025$0.05$0.10Beat
Jul 31, 2025-$0.10$0.06Beat
May 8, 2025-$0.03-$0.22Miss

Analyst view

Consensus price target
$39.00 ▲ +248.2%
Range $38.00 – $40.00
Rating: Buy
Buy 100% · Hold 0% · Sell 0%

Get free alerts on PHAR and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.